Investigational drug · Phase 3
BGB-B2033
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Liver Cancer, Hepatocellular Carcinoma, Hepatocellular Cancer.
Phase 3Last checked: Nov 20, 2026Latest source record: Nov 10, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
3
3 still active
All registered trials
3
Any phase or sponsor naming "BGB-B2033"
First trial start
2024
Jul 23, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "BGB-B2033", any sponsor or status.
Conditions studied
As listed on its trial records.
- Liver Cancer
- Hepatocellular Carcinoma
- Hepatocellular Cancer
- Metastatic Hepatocellular Carcinoma
- Local Advanced Hepatocellular Carcinoma
- Alpha-fetoprotein (AFP)-Producing Gastric Cancer
- Extragonadal Yolk Sac Tumors
- Glypican-3 (GPC3)-Positive Squamous Non-small Cell Lung Cancer
Approved drugs for the same conditions: Non-small cell lung cancer · Small cell lung cancer · Liver cancer (hepatocellular carcinoma) · Stomach and esophageal cancer · Oncology · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "BGB-B2033" as an intervention, largest first.
BeOne MedicinesBeOne Medicines (BeiGene) (ONC)
NCT06427941 · 630 participants (planned) · Start Jul 23, 2024 · Primary completion Mar 31, 2027
Drug: BGB-B2033; Tislelizumab and 1 more · For: Metastatic Hepatocellular Carcinoma; Local Advanced Hepatocellular Carcinoma; Alpha-fetoprotein (AFP)-Producing Gastric Cancer and 2 more
Sites: Birmingham, Alabama; Goodyear, Arizona; Duarte, California · 51 sites in all
- Study Comparing BGB-B2033 With Sorafenib or Lenvatinib in Advanced Hepatocellular CarcinomaPivotal-lookingRecruiting
BeOne MedicinesBeOne Medicines (BeiGene) (ONC)
NCT07836530 · 492 participants (planned) · Start Oct 23, 2026 · Primary completion Sep 21, 2029
Drug: BGB-B2033; Lenvatinib and 1 more · For: Hepatocellular Carcinoma; Liver Cancer
Sites: South Brisbane, Australia; Grafton, New Zealand
- Study Evaluating the Efficacy and Safety of BGB-B2033 in Participants With Advanced Hepatocellular CarcinomaNot yet recruiting
BeOne MedicinesBeOne Medicines (BeiGene) (ONC)
NCT07911683 · 100 participants (planned) · Start Nov 30, 2026 · Primary completion Mar 31, 2028
Drug: BGB-B2033 · For: Hepatocellular Cancer; Liver Cancer; Hepatocellular Carcinoma
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Liver Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from BeOne Medicines (BeiGene).
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.